This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Primary postoperative sedation based on propofol was compared with sedation based on dexmedetomidine. The drug dosage was defined by the hospital's protocols. Dexmedetomidine dosage was 1.5 micrograms per kilogram per hour, for a maximum of five days.
Location/setting
USA/secondary care.
Methods

Analytical approach:
The cost-effectiveness analysis was based on data from a study conducted between December 2008 and October 2010. The time horizon was the length of stay in hospital. The study perspective was not explicitly stated.
Effectiveness data:
The effectiveness data were the achievement of early extubation (defined as up to six hours after surgery), length of stay, and in-hospital mortality. The data were from a hospital's medical records database. Due to a recall of propofol vials, due to potential particulate contamination, the hospital switched from propofol to dexmedetomidine in November 2009; this created a before-and-after cohort. There were 978 patients who met the inclusion criteria of 18 years or older; admitted for cardiac surgery; received either study drug; and surgery of up to eight hours. From each drug group, 291 patients were randomly selected for analysis.
Monetary benefit and utility valuations:
Not relevant.
Measure of benefit:
There was no summary measure of benefit. The measures of benefit were the clinical outcomes: early extubation, length of stay, and in-hospital mortality.
Cost data:
The cost data were selected retrospectively from the observational hospital database. Total hospital charges and pharmacy charges, for each patient, were included. The costs were reported in US $.
